| ABIVAX SA EO -,01 |
| Frankreich |
| Gesundheit |
| FR0012333284 / A14UQC |
| 2X1 (Frankfurt) |
| FRA:2X1, ETR:2X1, 2X1:GR |
| - |
| https://www.abivax.com/ |
|
Abivax SA is a clinical-stage biotechnology company that develops therapeutics designed to harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Headquartered in Paris, Fra..
>Volltext.. |
| 7162.79 Mio. EUR |
| 6762.28 Mio. EUR |
| - |
| -301.22 Mio. EUR |
| -407.7 Mio. EUR |
| -5.32 EUR |
| 1.23 Mio. EUR |
| 394.26 Mio. EUR |
| -196.85 Mio. EUR |
| 5.61 |
| - |
| -126.13% |
| - |
| - |
| - |
| - |
| ABIVAX |
| 20.10.26 |
|
||||
|